Stoke Therapeutics, Inc. Common Stock Earnings Dividend
Earnings Summary
Revenue | $9.32Mn |
Net Profits | $-61.62Mn |
Net Profit Margins | -660.78% |
Stoke Therapeutics, Inc. Common Stock’s revenue fell -32.51% since last year same period to $9.32Mn in the Q2 2026. On a quarterly growth basis, Stoke Therapeutics, Inc. Common Stock has generated 49.7% jump in its revenue since last 3-months.
Stoke Therapeutics, Inc. Common Stock’s net profit fell -162.39% since last year same period to $-61.62Mn in the Q2 2026. On a quarterly growth basis, Stoke Therapeutics, Inc. Common Stock has generated -23.23% fall in its net profits since last 3-months.
Stoke Therapeutics, Inc. Common Stock’s net profit margin fell -288.79% since last year same period to -660.78% in the Q2 2026. On a quarterly growth basis, Stoke Therapeutics, Inc. Common Stock has generated 17.68% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
EPS Estimate Current Quarter | -0.82 |
EPS Estimate Current Year | -0.82 |
Stoke Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -0.82 - a 0% jump from last quarter’s estimates.
Stoke Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -0.82.
Key Ratios
Earning Per Share (EPS) | -0.93 |
Stoke Therapeutics, Inc. Common Stock’s earning per share (EPS) fell -132.5% since last year same period to -0.93 in the Q2 2026. This indicates that the Stoke Therapeutics, Inc. Common Stock has generated -132.5% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2026-05-07 | -0.82 | -0.79 | 3.66% |
2026-08-03 | -0.82 | -0.93 | -13.41% |
